In vitro activity of ertapenem against selected respiratory pathogens

Anna Marchese, L. Gualco, A. M. Schito, E. A. Debbia, G. C. Schito

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objectives: The in vitro activity of ertapenem was evaluated in comparison to 21 selected agents against a large collection of recently isolated respiratory tract pathogens including: 180 Streptococcus pneumoniae, 100 Streptococcus pyogenes, 70 Haemophilus influenzae, 70 Moraxella catarrhalis, 100 methicillin-susceptible Staphylococcus aureus and 30 Klebsiella pneumoniae. Additional in vitro tests (time-kill curves with ertapenem alone and in combination with four other agents) for S. pneumoniae were carried out. Methods: MIC determinations and time-kill curves were carried out following the procedures suggested by the NCCLS. Results: According to NCCLS susceptibility breakpoints, ertapenem was comparable to the most potent compounds tested for all pathogens studied. Ertapenem was 100% active against penicillin-susceptible and -intermediate S. pneumoniae and against 60% of penicillin-resistant strains. Time-kill tests at 4× MIC confirmed a pronounced bactericidal potency of ertapenem against these organisms. Interactions of ertapenem with several other agents against pneumococci resulted in clear synergic interactions (98.4%). Indifference was extremely rare and antagonism was not observed. All S. pyogenes strains tested were inhibited by ertapenem, irrespective of their macrolide resistance phenotypes. Ertapenem was also fully active against H. influenzae (100% susceptible) and M. catarrhalis (MIC90 0.015-0.03mg/L) even when capable of synthesizing β-lactamases. Methicillin-susceptible S. aureus and K. pneumoniae, including extended-spectrum β -lactamase-producing strains, were 100% susceptible to ertapenem. Conclusions: Our results indicate that ertapenem has a suitable spectrum of activity against organisms encountered in community-acquired bacterial respiratory tract infections.

Original languageEnglish
Pages (from-to)944-951
Number of pages8
JournalJournal of Antimicrobial Chemotherapy
Volume54
Issue number5
DOIs
Publication statusPublished - Nov 2004

Fingerprint

Streptococcus pneumoniae
Moraxella (Branhamella) catarrhalis
Methicillin
Streptococcus pyogenes
Haemophilus influenzae
Penicillins
In Vitro Techniques
ertapenem
Staphylococcal Pneumonia
Klebsiella
Macrolides
Klebsiella pneumoniae
Respiratory Tract Infections
Respiratory System
Staphylococcus aureus
Phenotype

Keywords

  • Bactericidal activity
  • Carbapenems
  • Interactions
  • Streptococcus pneumoniae
  • Time-kill

ASJC Scopus subject areas

  • Microbiology
  • Pharmacology

Cite this

Marchese, A., Gualco, L., Schito, A. M., Debbia, E. A., & Schito, G. C. (2004). In vitro activity of ertapenem against selected respiratory pathogens. Journal of Antimicrobial Chemotherapy, 54(5), 944-951. https://doi.org/10.1093/jac/dkh445

In vitro activity of ertapenem against selected respiratory pathogens. / Marchese, Anna; Gualco, L.; Schito, A. M.; Debbia, E. A.; Schito, G. C.

In: Journal of Antimicrobial Chemotherapy, Vol. 54, No. 5, 11.2004, p. 944-951.

Research output: Contribution to journalArticle

Marchese, A, Gualco, L, Schito, AM, Debbia, EA & Schito, GC 2004, 'In vitro activity of ertapenem against selected respiratory pathogens', Journal of Antimicrobial Chemotherapy, vol. 54, no. 5, pp. 944-951. https://doi.org/10.1093/jac/dkh445
Marchese, Anna ; Gualco, L. ; Schito, A. M. ; Debbia, E. A. ; Schito, G. C. / In vitro activity of ertapenem against selected respiratory pathogens. In: Journal of Antimicrobial Chemotherapy. 2004 ; Vol. 54, No. 5. pp. 944-951.
@article{357300d2d47e440f9643b8788d88537a,
title = "In vitro activity of ertapenem against selected respiratory pathogens",
abstract = "Objectives: The in vitro activity of ertapenem was evaluated in comparison to 21 selected agents against a large collection of recently isolated respiratory tract pathogens including: 180 Streptococcus pneumoniae, 100 Streptococcus pyogenes, 70 Haemophilus influenzae, 70 Moraxella catarrhalis, 100 methicillin-susceptible Staphylococcus aureus and 30 Klebsiella pneumoniae. Additional in vitro tests (time-kill curves with ertapenem alone and in combination with four other agents) for S. pneumoniae were carried out. Methods: MIC determinations and time-kill curves were carried out following the procedures suggested by the NCCLS. Results: According to NCCLS susceptibility breakpoints, ertapenem was comparable to the most potent compounds tested for all pathogens studied. Ertapenem was 100{\%} active against penicillin-susceptible and -intermediate S. pneumoniae and against 60{\%} of penicillin-resistant strains. Time-kill tests at 4× MIC confirmed a pronounced bactericidal potency of ertapenem against these organisms. Interactions of ertapenem with several other agents against pneumococci resulted in clear synergic interactions (98.4{\%}). Indifference was extremely rare and antagonism was not observed. All S. pyogenes strains tested were inhibited by ertapenem, irrespective of their macrolide resistance phenotypes. Ertapenem was also fully active against H. influenzae (100{\%} susceptible) and M. catarrhalis (MIC90 0.015-0.03mg/L) even when capable of synthesizing β-lactamases. Methicillin-susceptible S. aureus and K. pneumoniae, including extended-spectrum β -lactamase-producing strains, were 100{\%} susceptible to ertapenem. Conclusions: Our results indicate that ertapenem has a suitable spectrum of activity against organisms encountered in community-acquired bacterial respiratory tract infections.",
keywords = "Bactericidal activity, Carbapenems, Interactions, Streptococcus pneumoniae, Time-kill",
author = "Anna Marchese and L. Gualco and Schito, {A. M.} and Debbia, {E. A.} and Schito, {G. C.}",
year = "2004",
month = "11",
doi = "10.1093/jac/dkh445",
language = "English",
volume = "54",
pages = "944--951",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - In vitro activity of ertapenem against selected respiratory pathogens

AU - Marchese, Anna

AU - Gualco, L.

AU - Schito, A. M.

AU - Debbia, E. A.

AU - Schito, G. C.

PY - 2004/11

Y1 - 2004/11

N2 - Objectives: The in vitro activity of ertapenem was evaluated in comparison to 21 selected agents against a large collection of recently isolated respiratory tract pathogens including: 180 Streptococcus pneumoniae, 100 Streptococcus pyogenes, 70 Haemophilus influenzae, 70 Moraxella catarrhalis, 100 methicillin-susceptible Staphylococcus aureus and 30 Klebsiella pneumoniae. Additional in vitro tests (time-kill curves with ertapenem alone and in combination with four other agents) for S. pneumoniae were carried out. Methods: MIC determinations and time-kill curves were carried out following the procedures suggested by the NCCLS. Results: According to NCCLS susceptibility breakpoints, ertapenem was comparable to the most potent compounds tested for all pathogens studied. Ertapenem was 100% active against penicillin-susceptible and -intermediate S. pneumoniae and against 60% of penicillin-resistant strains. Time-kill tests at 4× MIC confirmed a pronounced bactericidal potency of ertapenem against these organisms. Interactions of ertapenem with several other agents against pneumococci resulted in clear synergic interactions (98.4%). Indifference was extremely rare and antagonism was not observed. All S. pyogenes strains tested were inhibited by ertapenem, irrespective of their macrolide resistance phenotypes. Ertapenem was also fully active against H. influenzae (100% susceptible) and M. catarrhalis (MIC90 0.015-0.03mg/L) even when capable of synthesizing β-lactamases. Methicillin-susceptible S. aureus and K. pneumoniae, including extended-spectrum β -lactamase-producing strains, were 100% susceptible to ertapenem. Conclusions: Our results indicate that ertapenem has a suitable spectrum of activity against organisms encountered in community-acquired bacterial respiratory tract infections.

AB - Objectives: The in vitro activity of ertapenem was evaluated in comparison to 21 selected agents against a large collection of recently isolated respiratory tract pathogens including: 180 Streptococcus pneumoniae, 100 Streptococcus pyogenes, 70 Haemophilus influenzae, 70 Moraxella catarrhalis, 100 methicillin-susceptible Staphylococcus aureus and 30 Klebsiella pneumoniae. Additional in vitro tests (time-kill curves with ertapenem alone and in combination with four other agents) for S. pneumoniae were carried out. Methods: MIC determinations and time-kill curves were carried out following the procedures suggested by the NCCLS. Results: According to NCCLS susceptibility breakpoints, ertapenem was comparable to the most potent compounds tested for all pathogens studied. Ertapenem was 100% active against penicillin-susceptible and -intermediate S. pneumoniae and against 60% of penicillin-resistant strains. Time-kill tests at 4× MIC confirmed a pronounced bactericidal potency of ertapenem against these organisms. Interactions of ertapenem with several other agents against pneumococci resulted in clear synergic interactions (98.4%). Indifference was extremely rare and antagonism was not observed. All S. pyogenes strains tested were inhibited by ertapenem, irrespective of their macrolide resistance phenotypes. Ertapenem was also fully active against H. influenzae (100% susceptible) and M. catarrhalis (MIC90 0.015-0.03mg/L) even when capable of synthesizing β-lactamases. Methicillin-susceptible S. aureus and K. pneumoniae, including extended-spectrum β -lactamase-producing strains, were 100% susceptible to ertapenem. Conclusions: Our results indicate that ertapenem has a suitable spectrum of activity against organisms encountered in community-acquired bacterial respiratory tract infections.

KW - Bactericidal activity

KW - Carbapenems

KW - Interactions

KW - Streptococcus pneumoniae

KW - Time-kill

UR - http://www.scopus.com/inward/record.url?scp=8844269107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8844269107&partnerID=8YFLogxK

U2 - 10.1093/jac/dkh445

DO - 10.1093/jac/dkh445

M3 - Article

C2 - 15472001

AN - SCOPUS:8844269107

VL - 54

SP - 944

EP - 951

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 5

ER -